These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 22172780)

  • 1. Aldosterone blockade in metabolic syndrome: hitting the target or still missing some links?
    Leung DY
    JACC Cardiovasc Imaging; 2011 Dec; 4(12):1250-2. PubMed ID: 22172780
    [No Abstract]   [Full Text] [Related]  

  • 2. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome.
    Kosmala W; Przewlocka-Kosmala M; Szczepanik-Osadnik H; Mysiak A; O'Moore-Sullivan T; Marwick TH
    JACC Cardiovasc Imaging; 2011 Dec; 4(12):1239-49. PubMed ID: 22172779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of spironolactone on diastolic function in hypertensive left ventricular hypertrophy.
    Gupta A; Schiros CG; Gaddam KK; Aban I; Denney TS; Lloyd SG; Oparil S; Dell'Italia LJ; Calhoun DA; Gupta H
    J Hum Hypertens; 2015 Apr; 29(4):241-6. PubMed ID: 25231508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of mineralocorticoid receptor antagonists on changes in cardiac structure and function of left ventricular dysfunction: a meta-analysis of randomized controlled trials.
    Li X; Qi Y; Li Y; Zhang S; Guo S; Chu S; Gao P; Zhu D; Wu Z; Lu L; Shen W; Jia N; Niu W
    Circ Heart Fail; 2013 Mar; 6(2):156-65. PubMed ID: 23400891
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spironolactone inhibits the transcardiac extraction of aldosterone in patients with congestive heart failure.
    Tsutamoto T; Wada A; Maeda K; Mabuchi N; Hayashi M; Tsutsui T; Ohnishi M; Sawaki M; Fujii M; Matsumoto T; Horie H; Sugimoto Y; Kinoshita M
    J Am Coll Cardiol; 2000 Sep; 36(3):838-44. PubMed ID: 10987608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade.
    Kosmala W; Przewlocka-Kosmala M; Szczepanik-Osadnik H; Mysiak A; Marwick TH
    Heart; 2013 Mar; 99(5):320-6. PubMed ID: 23343682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spironolactone improves diastolic function in the elderly.
    Roongsritong C; Sutthiwan P; Bradley J; Simoni J; Power S; Meyerrose GE
    Clin Cardiol; 2005 Oct; 28(10):484-7. PubMed ID: 16274097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldosterone blockade and heart failure.
    Jessup M
    N Engl J Med; 2003 Apr; 348(14):1380-2. PubMed ID: 12668698
    [No Abstract]   [Full Text] [Related]  

  • 9. Aldosterone blockade in patients with systolic left ventricular dysfunction.
    Pitt B
    Circulation; 2003 Oct; 108(15):1790-4. PubMed ID: 14557343
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of Spironolactone on Myocardial Fibrosis and Other Clinical Variables in Patients with Hypertrophic Cardiomyopathy.
    Maron MS; Chan RH; Kapur NK; Jaffe IZ; McGraw AP; Kerur R; Maron BJ; Udelson JE
    Am J Med; 2018 Jul; 131(7):837-841. PubMed ID: 29604289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacotherapy: Cardiovascular effects of aldosterone blockade in CKD.
    Pitt B
    Nat Rev Cardiol; 2009 Nov; 6(11):679-80. PubMed ID: 19851348
    [No Abstract]   [Full Text] [Related]  

  • 12. High serum level of procollagen type III amino-terminal peptide contributes to the efficacy of spironolactone and angiotensin-converting enzyme inhibitor therapy on left ventricular hypertrophy in essential hypertensive patients.
    Sato A; Takane H; Saruta T
    Hypertens Res; 2001 Mar; 24(2):99-104. PubMed ID: 11325081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of aldosterone receptor antagonist eplerenone in aortic stenosis.
    Ramaraj R
    Am Heart J; 2009 Mar; 157(3):e13; author reply e17. PubMed ID: 19249404
    [No Abstract]   [Full Text] [Related]  

  • 14. [Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction].
    Hayashi M
    J Cardiol; 2004 Feb; 43(2):88-91. PubMed ID: 15046031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MY APPROACH to the patient with heart failure and improved ejection fraction
    Cohn JN
    Trends Cardiovasc Med; 2018 Feb; 28(2):153. PubMed ID: 29032935
    [No Abstract]   [Full Text] [Related]  

  • 16. Do diuretics and aldosterone receptor antagonists improve ventricular remodeling?
    Pitt B
    J Card Fail; 2002 Dec; 8(6 Suppl):S491-3. PubMed ID: 12555163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
    Udelson JE; Feldman AM; Greenberg B; Pitt B; Mukherjee R; Solomon HA; Konstam MA
    Circ Heart Fail; 2010 May; 3(3):347-53. PubMed ID: 20299607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary aldosteronism and low-renin hypertension: a continuum?
    Funder JW
    Nephrol Dial Transplant; 2013 Jul; 28(7):1625-7. PubMed ID: 23535225
    [No Abstract]   [Full Text] [Related]  

  • 19. Blocking aldosterone in heart failure.
    Shafiq MM; Miller AB
    Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):379-85. PubMed ID: 19661156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Aldosterone receptor antagonists in heart failure. Rightly brought back from retirement].
    Kolloch R; Offers E
    MMW Fortschr Med; 2003 Nov; 145(47):42-4, 47. PubMed ID: 14725033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.